<DOC>
	<DOCNO>NCT01709149</DOCNO>
	<brief_summary>The purpose research study evaluate safety effectiveness CK-2017357 take without riluzole ( also call Rilutek® ) patient Amyotrophic Lateral Sclerosis ( ALS ) .</brief_summary>
	<brief_title>Study Safety , Tolerability &amp; Efficacy CK-2017357 Amyotrophic Lateral Sclerosis ( ALS )</brief_title>
	<detailed_description>The length study , include screening , dose , follow-up , approximately 20 week . After one-week open-label phase patient receive CK-2017357 125 milligram ( mg ) twice daily , patient randomize one one ( fifty-fifty ) receive double-blind CK-2017357 matching placebo . The CK-2017357/placebo dose increase faster weekly patient 's high tolerate daily dose , maximum 250 mg twice daily . The dose may decrease base tolerability . Patients continue treatment high tolerate dose complete total 12 week double-blind treatment . Patients may riluzole riluzole study entry . Patients riluzole must stay riluzole . Patients riluzole get double-blind CK-2017357 give riluzole half label dosage ( 50 mg day instead 50 mg twice day ) . Blood test safety perform . Information side effect may occur also collect .</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Motor Neuron Disease</mesh_term>
	<mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
	<mesh_term>Riluzole</mesh_term>
	<criteria>1 . Able comprehend willing sign Informed Consent Form ( ICF ) 2 . Male female 18 year age old 3 . A diagnosis familial sporadic ALS ( define meeting possible , laboratorysupported probable , probable , definite criterion diagnosis ALS accord World Federation Neurology El Escorial criterion ) 4 . Upright Slow Vital Capacity ( SVC ) &gt; 60 % predicted age , height sex 5 . At least 4 12 ALSFRSR question must score 2 3 6 . Diminished measurable maximum voluntary grip strength least one hand ; i.e. , 10 40 pound ( female ) 10 60 pound ( male ) 7 . Able swallow tablet without crush 8 . A caregiver ( one need ) observe report patient 's status 9 . Prestudy clinical laboratory finding within normal range , outside normal range , deem clinically significant Investigator 10 . Male patient must agree duration study 10 week end study use condom sexual intercourse female partner reproductive potential female partner use additional effective mean contraception ( e.g. , diaphragm plus spermicide , oral contraceptive ) male patient must agree abstain sexual intercourse 10 week end study 11 . Female patient must postmenopausal ( ≥ 1 year ) sterilize , , childbearing potential , breastfeeding , negative pregnancy test , intention become pregnant course study , use contraceptive drug device detail item 10 duration study 10 week end study 12 . Patients must either stable dose riluzole 50 mg twice daily least 30 day prior screen take riluzole least 30 day prior screen willing begin riluzole use conduct study . 1 . Any use noninvasive positive pressure ventilation ( NIPPV , e.g . continuous positive airway pressure [ CPAP ] bilevel positive airway pressure [ BiPAP ] ) portion day , mechanical ventilation via tracheostomy , form oxygen supplementation 2 . Patients diaphragm pace system ( DPS ) study entry anticipate DPS placement course study 3 . Body Mass Index ( BMI ) 19.0 kg/m2 low 4 . Unwilling discontinue theophyllinecontaining medication study participation 5 . Serum chloride &lt; 100 mmol/L 6 . Neurological impairment due condition ALS , include history transient ischemic attack ( TIA ) within past year 7 . Presence screen medically significant cardiac , pulmonary , gastrointestinal ( GI ) , musculoskeletal , psychiatric illness might interfere patient 's ability comply study procedure might confound interpretation clinical safety efficacy data 8 . Has take investigational study drug within 30 day 5 halflives prior agent , whichever great , prior dose 9 . Previously receive CK2017357 previous clinical trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>